Business Wire

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)

Del

HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence, is proud to announce its participation as an exhibitor at the upcoming 2018 European Society of Cardiology Congress (ESC). The Congress will take place at Messe Munich International in Munich, Germany and will run from August 25 to August 29, 2018. HeartSciences will highlight its MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device as well as recent clinical study results published in the Journal of the American College of Cardiology (JACC)

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005047/en/

MyoVista Wavelet ECG 12-Lead Cardiac Testing Device (Photo: Business Wire)

MyoVista Wavelet ECG 12-Lead Cardiac Testing Device (Photo: Business Wire)

The JACC article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presented the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista ® Wavelet ECG as a diagnostic tool for predicting myocardial relaxation abnormalities. Results from the study demonstrate MyoVista’s patented technology based on CWT signal processing can detect myocardial relaxation abnormalities associated with LVDD.

About HeartSciences

HeartSciences is advancing the field of electrocardiography through the application of wavelet signal processing and artificial intelligence to develop next generation ECG technology. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wavECG Cardiac Testing Device is a 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.

In addition to the proprietary informatics, the MyoVista wavECG Device also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training as well as easy and intuitive use. The MyoVista wavECG Device is not currently approved for sale or distribution in the United States and is not currently FDA cleared.

HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit www.heartsciences.com.

Contact information

HeartSciences
Gene Gephart, +1-737-346-1089
gene.gephart@heartsciences.com
or
Investor Contact
Zimmons International Communications
Jennifer K. Zimmons, +1-917-214-3514
jzimmons@zimmonsic.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00Pressemelding

Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp

Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00Pressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te

Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00Pressemelding

Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented

Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00Pressemelding

Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00Pressemelding

Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of

Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 13:13:00Pressemelding

Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.